Home/Filings/4/0000950170-25-111241
4//SEC Filing

Kastelein Johannes Jacob Pieter 4

Accession 0000950170-25-111241

CIK 0001936258other

Filed

Aug 24, 8:00 PM ET

Accepted

Aug 25, 5:04 PM ET

Size

9.5 KB

Accession

0000950170-25-111241

Insider Transaction Report

Form 4
Period: 2025-08-21
Kastelein Johannes Jacob Pieter
DirectorChief Scientific Officer
Transactions
  • Sale

    Ordinary Shares

    2025-08-22$25.08/sh42,342$1,061,93776,960 total(indirect: See footnote)
  • Sale

    Ordinary Shares

    2025-08-21$24.29/sh50,000$1,214,500119,302 total(indirect: See footnote)
  • Sale

    Ordinary Shares

    2025-08-22$25.49/sh7,658$195,20269,302 total(indirect: See footnote)
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.73 per share to $24.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F2]The ordinary shares are held by Futurum B.V. ("Futurum") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.39 per share to $25.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.39 per share to $25.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

Documents

1 file

Issuer

NewAmsterdam Pharma Co N.V.

CIK 0001936258

Entity typeother

Related Parties

1
  • filerCIK 0002000389

Filing Metadata

Form type
4
Filed
Aug 24, 8:00 PM ET
Accepted
Aug 25, 5:04 PM ET
Size
9.5 KB